FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136163480> ?p ?o ?g. }

• W3136163480 endingPage "e046352" @default.
• W3136163480 startingPage "e046352" @default.
• W3136163480 abstract "Objectives Despite remarkable advances in the treatment of oesophageal cancer (OC), the role of antiepidermal growth factor receptor (anti-EGFR) agents in treating OC remains controversial. Herein, a systematic review and meta-analysis were conducted to elucidate the efficacy and safety of anti-EGFR agents in patients with OC. Design Meta-analysis of randomised controlled trials (RCTs) identified by searching the PubMed, Embase, Web of Science, ClinicalTrials.gov, Cochrane Library, Chinese Biology Medicine, China National Knowledge Infrastructure and Wanfang Data Knowledge Service Platform databases from inception to December 2019. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Setting RCTs from any country and healthcare setting. Participants Patients with OC. Interventions Combination therapy with anti-EGFR agents and conventional treatments versus conventional treatments alone in patients with OC. Primary and secondary outcome measures Overall survival (OS) and progression-free survival (PFS) were primary outcome measures, and objective response rate (ORR), disease control rate (DCR) and treatment toxicities were secondary outcome measures. Results In total, 25 RCTs comprising 3406 patients with OC were included. Overall, anti-EGFR treatment significantly improved the OS (HR: 0.81, 95% CI 0.74 to 0.89, p<0.00001), ORR (relative risk (RR): 1.33, 95% CI 1.16 to 1.52, p<0.0001) and DCR (RR: 1.22, 95% CI 1.11 to 1.34, p<0.0001) but not PFS (HR: 0.91, 95% CI 0.76 to 1.08, p=0.26). Anti-EGFR treatment was significantly associated with higher incidences of myelosuppression, diarrhoea, acne-like rash and hypomagnesaemia. Conclusions Overall, anti-EGFR agents have positive effects on OS, the ORR and DCR in OC. However, considering the high incidence of adverse effects, such as myelosuppression, diarrhoea, acne-like rashes and hypomagnesaemia, careful monitoring of patients with OC is recommended during anti-EGFR treatment. Trial registration number CRD42020169230." @default.
• W3136163480 created "2021-03-29" @default.
• W3136163480 creator A5008080186 @default.
• W3136163480 creator A5038871287 @default.
• W3136163480 creator A5060585083 @default.
• W3136163480 creator A5061402622 @default.
• W3136163480 creator A5061478170 @default.
• W3136163480 creator A5066532132 @default.
• W3136163480 creator A5078526337 @default.
• W3136163480 creator A5083716693 @default.
• W3136163480 creator A5084514412 @default.
• W3136163480 creator A5089041639 @default.
• W3136163480 date "2021-03-01" @default.
• W3136163480 modified "2023-10-12" @default.
• W3136163480 title "Efficacy and safety of anti-epidermal growth factor receptor agents for the treatment of oesophageal cancer: a systematic review and meta-analysis" @default.
• W3136163480 cites W1630182881 @default.
• W3136163480 cites W1841144092 @default.
• W3136163480 cites W1870988441 @default.
• W3136163480 cites W1896328454 @default.
• W3136163480 cites W1975813492 @default.
• W3136163480 cites W1979073879 @default.
• W3136163480 cites W2012824370 @default.
• W3136163480 cites W2019236425 @default.
• W3136163480 cites W2028009636 @default.
• W3136163480 cites W2042469467 @default.
• W3136163480 cites W2044404885 @default.
• W3136163480 cites W2049309222 @default.
• W3136163480 cites W2060819673 @default.
• W3136163480 cites W2070103786 @default.
• W3136163480 cites W2074937425 @default.
• W3136163480 cites W2087149654 @default.
• W3136163480 cites W2101076600 @default.
• W3136163480 cites W2106812029 @default.
• W3136163480 cites W2108572537 @default.
• W3136163480 cites W2112062992 @default.
• W3136163480 cites W2113814947 @default.
• W3136163480 cites W2117223681 @default.
• W3136163480 cites W2124495521 @default.
• W3136163480 cites W2142279958 @default.
• W3136163480 cites W2146269511 @default.
• W3136163480 cites W2153534791 @default.
• W3136163480 cites W2156098321 @default.
• W3136163480 cites W2160893354 @default.
• W3136163480 cites W2162616129 @default.
• W3136163480 cites W2166559675 @default.
• W3136163480 cites W2272984102 @default.
• W3136163480 cites W2292308194 @default.
• W3136163480 cites W2547086728 @default.
• W3136163480 cites W2580827699 @default.
• W3136163480 cites W2587916991 @default.
• W3136163480 cites W2724177236 @default.
• W3136163480 cites W2768310080 @default.
• W3136163480 cites W2769696597 @default.
• W3136163480 cites W2790015936 @default.
• W3136163480 cites W2795734554 @default.
• W3136163480 cites W2889646458 @default.
• W3136163480 cites W2903157955 @default.
• W3136163480 cites W2903799428 @default.
• W3136163480 cites W2904817374 @default.
• W3136163480 cites W2939241793 @default.
• W3136163480 cites W2991792334 @default.
• W3136163480 cites W4211048478 @default.
• W3136163480 cites W4297851560 @default.
• W3136163480 doi "https://doi.org/10.1136/bmjopen-2020-046352" @default.
• W3136163480 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7986677" @default.
• W3136163480 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33753446" @default.
• W3136163480 hasPublicationYear "2021" @default.
• W3136163480 type Work @default.
• W3136163480 sameAs 3136163480 @default.
• W3136163480 citedByCount "1" @default.
• W3136163480 countsByYear W31361634802021 @default.
• W3136163480 crossrefType "journal-article" @default.
• W3136163480 hasAuthorship W3136163480A5008080186 @default.
• W3136163480 hasAuthorship W3136163480A5038871287 @default.
• W3136163480 hasAuthorship W3136163480A5060585083 @default.
• W3136163480 hasAuthorship W3136163480A5061402622 @default.
• W3136163480 hasAuthorship W3136163480A5061478170 @default.
• W3136163480 hasAuthorship W3136163480A5066532132 @default.
• W3136163480 hasAuthorship W3136163480A5078526337 @default.
• W3136163480 hasAuthorship W3136163480A5083716693 @default.
• W3136163480 hasAuthorship W3136163480A5084514412 @default.
• W3136163480 hasAuthorship W3136163480A5089041639 @default.
• W3136163480 hasBestOaLocation W31361634801 @default.
• W3136163480 hasConcept C126322002 @default.
• W3136163480 hasConcept C143998085 @default.
• W3136163480 hasConcept C168563851 @default.
• W3136163480 hasConcept C17744445 @default.
• W3136163480 hasConcept C187960798 @default.
• W3136163480 hasConcept C189708586 @default.
• W3136163480 hasConcept C199539241 @default.
• W3136163480 hasConcept C2776478404 @default.
• W3136163480 hasConcept C2779473830 @default.
• W3136163480 hasConcept C44249647 @default.
• W3136163480 hasConcept C71924100 @default.
• W3136163480 hasConcept C82789193 @default.
• W3136163480 hasConcept C95190672 @default.
• W3136163480 hasConceptScore W3136163480C126322002 @default.
• W3136163480 hasConceptScore W3136163480C143998085 @default.

• next